Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment.

• Hypertension is a major risk factor of Alzheimer's disease (AD); however, controlled studies on the effect of antihypertensive treatment on the risk of dementia are inconclusive. Therefore, a biological marker that predicts individual response to antihypertensive treatment would be of high clinical relevance. Midregional proatrial natriuretic peptide (MR-proANP), an inactive surrogate molecule of the mature atrial natriuretic peptide, is related to circulatory function and hypertension.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Nyckelord

Aged

Alzheimer Disease

etiology

Antihypertensive Agents

adverse effects

Atrial Natriuretic Factor

metabolism

Blood Pressure

drug effects

Cognition Disorders

metabolism

physiopathology

Disease Progression

Female

Humans

Hypertension

drug therapy

Kaplan-Meier Estimate

Longitudinal Studies

Male

Middle Aged

Regression Analysis

Retrospective Studies

Alzheimer's disease

antihypertensive therapy

antihypertensive

treatment

microcirculatory function

mild cognitive impairment

MR-proANP

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)